Advertisement

European Journal of Nutrition

, Volume 58, Issue 8, pp 3379–3380 | Cite as

Activation of T-regulatory cells by a synbiotic may be important for its anti-inflammatory effect

  • Jiezhong Chen
  • Luis VitettaEmail author
Letter to the Editor
  • 35 Downloads

We read with great interest Moser and colleagues’ paper entitled “Effects of an oral synbiotic on the gastrointestinal immune system and microbiota in patients with diarrhea-predominant irritable bowel syndrome” published in your journal [1]. The results showed that the synbiotic reduced the symptoms of irritable bowel syndrome (IBS) with increased microbiota diversity and decreased inflammatory status. The synbiotic increased butyrate, a key anti-inflammatory metabolite produced by intestinal commensal bacteria and decreased zonulin, an indicator of intestinal permeability. However, regulatory T-cells (T-Reg cells) changes by the synbiotic were not observed in this study although CD4 T-cells were significantly decreased. As activation of T-Reg cells by butyrate plays a key role in the intestinal inflammatory status [2], it would be interesting to further investigate the reasons as to why they were not altered in this study. We think that this may be related with a pre-existing...

References

  1. 1.
    Moser AM, Spindelboeck W, Halwachs B, Strohmaier H, Kump P, Gorkiewicz G, Hogenauer C (2018) Effects of an oral synbiotic on the gastrointestinal immune system and microbiota in patients with diarrhea-predominant irritable bowel syndrome. Eur J Nutr.  https://doi.org/10.1007/s00394-018-1826-7 CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Chen J, Vitetta L (2018) Inflammation-modulating effect of butyrate in the prevention of colon cancer by dietary fiber. Clin Colorectal Cancer 17(3):e541–e544CrossRefGoogle Scholar
  3. 3.
    Ford AC, Lacy BE, Talley NJ (2017) Irritable bowel syndrome. N Engl J Med 376(26):2566–2578CrossRefGoogle Scholar
  4. 4.
    Tap J, Derrien M, Tornblom H, Brazeilles R, Cools-Portier S, Dore J, Storsrud S, Le Neve B, Ohman L, Simren M (2017) Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome. Gastroenterology 152(1):111–123e118CrossRefGoogle Scholar
  5. 5.
    Shariati A, Fallah F, Pormohammad A, Taghipour A, Safari H, Chirani AS, Sabour S, Alizadeh-Sani M, Azimi T (2019) The possible role of bacteria, viruses, and parasites in initiation and exacerbation of irritable bowel syndrome. J Cell Physiol 234(6):8550–8569CrossRefGoogle Scholar
  6. 6.
    Lee MK, Xu S, Fitzpatrick EH, Sharma A, Graves HL, Czerniecki BJ (2013) Inhibition of CD4+ CD25+ regulatory T cell function and conversion into Th1-like effectors by a Toll-like receptor-activated dendritic cell vaccine. PLoS One 8(11):e74698CrossRefGoogle Scholar
  7. 7.
    Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL, Bortey E, Forbes WP (2011) Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 364(1):22–32CrossRefGoogle Scholar
  8. 8.
    Lembo A, Pimentel M, Rao SS, Schoenfeld P, Cash B, Weinstock LB, Paterson C, Bortey E, Forbes WP (2016) Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome. Gastroenterology 151(6):1113–1121CrossRefGoogle Scholar
  9. 9.
    Fuke N, Aizawa K, Suganuma H, Takagi T, Naito Y (2017) Effect of combined consumption of Lactobacillus brevis KB290 and beta-carotene on minor diarrhoea-predominant irritable bowel syndrome-like symptoms in healthy subjects: a randomised, double-blind, placebo-controlled, parallel-group trial. Int J Food Sci Nutr 68(8):973–986CrossRefGoogle Scholar
  10. 10.
    Alrafas HR, Busbee PB, Nagarkatti M, Nagarkatti PS (2019) Resveratrol modulates the gut microbiota to prevent murine colitis development through induction of Tregs and suppression of Th17 cells. J Leukoc Biol 106(2):467–480.  https://doi.org/10.1002/JLB.3A1218-476RR CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Medlab Clinical LtdSydneyAustralia
  2. 2.Faculty of Medicine and HealthThe University of SydneySydneyAustralia

Personalised recommendations